Primary Breast Diffuse Large B Cell Lymphoma: Summarization of 12 Cases.

Ying Huang; Li Wang; Lei Fan; Tian Tian; Xiao-yan QU; Ji XU; Run Zhang; Wei XU; Jian-yong LI

Return

Primary Breast Diffuse Large B Cell Lymphoma: Summarization of 12 Cases.

Author: Ying HUANG ¹ ; Li WANG ¹ ; Lei FAN ¹ ; Tian TIAN ¹ ; Xiao-Yan QU ¹ ; Ji XU ¹ ; Run ZHANG ¹ ; Wei XU ¹ ; Jian-Yong LI ²
Author Information

1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China.
2. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China. E-mail: lijianyonglm@ medmail.com.cn.
Publication Type:Journal Article
MeSH: Breast Neoplasms; diagnosis; pathology; therapy; Humans; Lymphoma, Large B-Cell, Diffuse; diagnosis; pathology; therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate
From: Journal of Experimental Hematology 2016;24(2):452-456
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the clinicopathological manifestation, immunophenotypic features and prognostic factors of patients with primary breast DLBCL (PB-DLBCL).
METHODSTwelve cases of PB-DLBCL, diagnosed according to the 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissues, were retrospectively studied.
RESULTSMost patients were admitted to hospital because of painless unilateral breast mass. Out of 12 cases, 5 were in Ann Arbor stage I (41.7%), 7 case were in stage II (58.3%). Most (89.9%) were assigned to non-GCB subtypes, 11.1% were classified as GCB subtype. The patients who recepted treatment were sensitive to chemotherapy and they were all alive following 12 to 92 months.
CONCLUSIONPrimary breast DLBCL is extremely rare without specific clinical features. They all respond well to chemotherapy and show good prognosis.